Roivant Sciences Investor Relations Material

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company established in 2014, dedicated to the development and commercialization of innovative medicines and technologies, particularly in the areas of inflammation and immunology. The company adopts a unique model, creating nimble and focused subsidiaries known as "Vants" for the development and commercialization of its medicines and technologies. This model has enabled Roivant to bring to market treatments like VTAMA® (tapinarof cream, 1%) for plaque psoriasis in adults, and to advance a diverse pipeline of investigational drugs across its family of companies, including fully human monoclonal antibodies and treatments for autoimmune diseases. Roivant Sciences is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.